{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:02:18Z","timestamp":1787022138226,"version":"build-2736575974"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Several randomized controlled trials compared adjuvant systemic chemotherapy with observation in patients with resected biliary tract cancer (BTC) have yielded inconsistent outcomes. In order to assess the efficacy of adjuvant therapy in these patients, we conducted this systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a thorough search in various databases, which included MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, ASCO Abstracts, ESMO Abstracts and ClinicalTrials.gov. All relevant randomized controlled trials investigating the adjuvant chemotherapy compared with observation in resected biliary tract cancer were identified. The primary outcome of interest was overall survival (OS), while secondary outcome was relapse-free survival (RFS). Statistical analyses were conducted using Review Manager 5.3. Additionally, publication bias was evaluated using Egger\u2019s test in Stata 12.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 5 randomized controlled trials, involving 1406 patients, were included in this analysis. Compared with observation, adjuvant chemotherapy improved RFS [HR 0.84 (0.73-0.96), p=0.01] (I\n                      <jats:sup>2<\/jats:sup>\n                      =0%, p=0.89) but not OS [HR 0.89 (0.77-1.03), p=0.12] (I\n                      <jats:sup>2<\/jats:sup>\n                      =51%, p=0.09) in the entire population after BTC resection. Subgroup analyses revealed that adjuvant chemotherapy did improve both OS [HR 0.76 (0.62-0.93), p=0.009] (I\n                      <jats:sup>2<\/jats:sup>\n                      =7%, p=0.37) and RFS [HR 0.74 (0.58-0.95), p=0.02] (I\n                      <jats:sup>2<\/jats:sup>\n                      =0%, p=0.39) in patients with lymph node positivity. Furthermore, patients receiving oral fluoropyrimidine monotherapy showed benefit from the adjuvant therapy, with longer OS [HR 0.78 (0.65-0.94), p=0.009] (I\n                      <jats:sup>2<\/jats:sup>\n                      =2%, p=0.31) and RFS [HR 0.81 (0.68-0.95), p=0.01] (I\n                      <jats:sup>2<\/jats:sup>\n                      =0%, p=0.95).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>To conclude, adjuvant chemotherapy have the potential to offer advantages in patients with resected BTC. Specifically, patients demonstrating positive lymph node status have a higher likelihood of benefiting from adjuvant therapy. Our analysis supports the current standard of care of adjuvant fluoropyrimidine. However, the recommendation of oral fluoropyrimidine monotherapy as the preferred option is not definitive, as it is based on limited studies. Further validation of these outcomes is necessary by conducting extensive randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0295583","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T13:33:37Z","timestamp":1745415217000},"page":"e0295583","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adjuvant chemotherapy compared with observation in patients with resected biliary tract cancer: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1371","volume":"20","author":[{"given":"Liying","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daidi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4028-3240","authenticated-orcid":true,"given":"Linjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"issue":"10272","key":"pone.0295583.ref001","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"JW Valle","year":"2021","journal-title":"Lancet"},{"issue":"10372","key":"pone.0295583.ref002","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"K Nakachi","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"pone.0295583.ref003","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bpg.2015.02.006","article-title":"Pathologic classification of cholangiocarcinoma: new concepts","volume":"29","author":"Y Nakanuma","year":"2015","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"9","key":"pone.0295583.ref004","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"JM Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"pone.0295583.ref005","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/ags3.12266","article-title":"Essential updates to the surgical treatment of biliary tract cancer","volume":"3","author":"S Matsukuma","year":"2019","journal-title":"Ann Gastroenterol Surg"},{"issue":"16","key":"pone.0295583.ref006","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"AM Horgan","year":"2012","journal-title":"J Clin Oncol"},{"key":"pone.0295583.ref007","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"JF Tierney","year":"2007","journal-title":"Trials"},{"issue":"9128","key":"pone.0295583.ref008","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"D Moher","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"pone.0295583.ref009","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"T Ebata","year":"2018","journal-title":"Br J Surg"},{"issue":"8","key":"pone.0295583.ref010","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"J Edeline","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0295583.ref011","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11605-021-05143-6","article-title":"Prospective randomized controlled trial comparing adjuvant chemotherapy vs. no chemotherapy for patients with carcinoma of gallbladder undergoing curative resection","volume":"26","author":"SS Saluja","year":"2022","journal-title":"J Gastrointest Surg"},{"issue":"18","key":"pone.0295583.ref012","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study","volume":"40","author":"J Bridgewater","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"pone.0295583.ref013","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"JN Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"pone.0295583.ref014","doi-asserted-by":"crossref","first-page":"100354","DOI":"10.1016\/j.ctarc.2021.100354","article-title":"Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review","volume":"27","author":"A Rizzo","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"pone.0295583.ref015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102389","article-title":"Impact of positive lymph nodes and resection margin status on the overall survival of patients with resected perihilar cholangiocarcinoma: the ENSCCA registry","volume":"14","author":"LE Nooijen","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"pone.0295583.ref016","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jhep.2022.10.021","article-title":"Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma","volume":"78","author":"C Sposito","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"pone.0295583.ref017","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/bjs.10415","article-title":"Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer","volume":"104","author":"S Yamashita","year":"2017","journal-title":"Br J Surg"},{"key":"pone.0295583.ref018","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14041026","article-title":"Prognostic and predictive molecular markers in cholangiocarcinoma","volume":"14","author":"S Pavicevic","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"pone.0295583.ref019","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030558","article-title":"PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer","volume":"13","author":"A Rizzo","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"pone.0295583.ref020","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00262-022-03349-4","article-title":"Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis","volume":"72","author":"M Santoni","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"pone.0295583.ref021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"A Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10391","key":"pone.0295583.ref022","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"RK Kelley","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"pone.0295583.ref023","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.3390\/curroncol30040280","article-title":"Immunotherapy in early-stage non-small cell lung cancer (NSCLC): current evidence and perspectives","volume":"30","author":"C Lazzari","year":"2023","journal-title":"Curr Oncol"},{"issue":"18","key":"pone.0295583.ref024","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1097\/CM9.0000000000002371","article-title":"Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy","volume":"135","author":"Y Yan","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"pone.0295583.ref025","doi-asserted-by":"crossref","first-page":"100335","DOI":"10.1016\/j.ctarc.2021.100335","article-title":"First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 Trial: \u201cAnd Yet It Moves!\u201d","volume":"27","author":"A Rizzo","year":"2021","journal-title":"Cancer Treat Res Commun"},{"issue":"2","key":"pone.0295583.ref026","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1349-7006.2010.01793.x","article-title":"Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients","volume":"102","author":"B Chuah","year":"2011","journal-title":"Cancer Sci"},{"issue":"9","key":"pone.0295583.ref027","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","article-title":"Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial","volume":"28","author":"JA Ajani","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T13:34:00Z","timestamp":1745415240000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295583"}},"subtitle":[],"editor":[{"given":"Jincheng","family":"Wang,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0295583","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]}}}